

## Take-home messages

- ▶ Despite congenital infection with HHV-6 having an established prevalence of 1%, there are few reports associating HHV-6 to disease in fetuses.
- ▶ HHV-6 has been implicated in myocarditis in adults and children, but there was no previous association with myocarditis in fetuses.
- ▶ The virus-induced myocardial injury and the subsequent reparative lesions in the heart in development may be the cause of structural cardiac defects in fetuses.

We consider that in our case, the presence of HHV-6 DNA in the myocardium, in the absence of other pathogens, suggests that the myocarditis was caused by the virus. Moreover, we suggest that the identification of the viral genome is favourable to a pathogenic relationship between the virus and the cardiac anomaly.

In our case, there are pathological findings of acute, subacute and chronic myocarditis compatible with viral persistence. The infection probably occurred early in the second trimester of pregnancy. We postulate that the virus-induced myocardial injury and the subsequent reparative lesions in the heart in development may be the cause of structural cardiac defects in this fetus.

Carla Ramalho,<sup>1</sup> José Monterroso,<sup>2</sup>  
Joana Simões,<sup>3</sup> Otilia Brandão,<sup>4</sup>  
Nuno Montenegro<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Cardiovascular Research & Development Unit, Hospital S. João, Faculdade de Medicina do Porto; <sup>2</sup>Department of Pediatric Cardiology, Hospital S. João, Porto, Portugal; <sup>3</sup>Department of Microbiology, Hospital S. João, Porto, Portugal; <sup>4</sup>Department of Pathology, Hospital S. João, Porto, Portugal

**Correspondence to** Carla Ramalho, Serviço de Obstetria, Hospital S. João, Al. Prof. Hérnani Monteiro, 4202-451 Porto, Portugal; [carlaramalho@med.up.pt](mailto:carlaramalho@med.up.pt)

**Competing interests** None.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

Published Online First 30 March 2011

*J Clin Pathol* 2011; **64**:733–734.  
doi:10.1136/jcp.2010.087494

## REFERENCES

1. Comar M, D'Agaro P, Campello C, *et al*. Human herpes virus 6 in archival cardiac tissues from children with idiopathic dilated cardiomyopathy or congenital heart disease. *J Clin Pathol* 2009; **62**:80–3.
2. Hall CB, Caserta MT, Schnabel KC, *et al*. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7). *J Pediatr* 2004; **145**:472–7.

3. Ashshi AM, Cooper RJ, Klapper PE, *et al*. Detection of human herpes virus 6 DNA in fetal hydrops. *Lancet* 2000; **355**:1519–20.
4. Yoshikawa T, Ihira M, Suzuki K, *et al*. Fatal acute myocarditis in an infant with human herpesvirus 6 infection. *J Clin Pathol* 2001; **54**:792–5.
5. Fukae S, Ashizawa N, Morikawa S, *et al*. A fatal case of fulminant myocarditis with human herpesvirus-6 infection. *Intern Med* 2000; **39**:632–6.
6. Rohayem J, Dinger J, Fischer R, *et al*. Fatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection. *J Clin Microbiol* 2001; **39**:4585–7.
7. Chang YL, Parker ME, Nuovo G, *et al*. Human herpesvirus 6-related fulminant myocarditis and hepatitis in an immunocompetent adult with fatal outcome. *Hum Pathol* 2009; **40**:740–5.
8. Bigalke B, Klingel K, May AE, *et al*. Human herpesvirus 6 subtype A-associated myocarditis with 'apical ballooning'. *Can J Cardiol* 2007; **23**:393–5.

### Progressive macular hypomelanosis Guillet-Héléon: structural and immunohistochemical findings


In 1985 and 1988, Gerard Guillet and Raymond Héléon, with colleagues, described a novel acquired hypopigmentation disorder in dark-skinned immigrants from the Caribbean which they named progressive macular hypomelanosis (PMH).<sup>1,2</sup> Over the past 20 years, many other terms have been coined for this condition, including cutis trunci variata, nummular and confluent hypomelanosis, Creole dyschromia, or idiopathic multiple large-macule hypomelanosis.<sup>3</sup> More than 600 PMH patients have

been reported in the literature with skin phototypes II–VI, but the debate about the aetiology of this disorder is still open.

We present an immunohistochemical and ultrastructural study on disseminated PMH extending beyond the trunk. No *Propionibacterium* colonisation of skin was found despite extensive examination. The evidence for a bacterial origin is discussed in consideration of the literature.

A 29-year-old Romanian female patient (skin phototype III), who had relocated to Germany 8 years earlier, presented with a mottled hypopigmentation of her skin that had progressed over the past 12 years. At the age of 17, macules started to appear on the abdomen and then spread gradually to the flanks, axillae and back. Over the past 2 years, the patient had noticed a rapid progression to the neck, décolleté and groin without any subjective symptoms. Physical examination revealed multiple partially coalescing oval or irregular hypopigmented macules ranging in diameter from 1 to 5 cm without any scaling (figure 1A). There was no fluorescence under illumination with Wood's light (figure 1B). Other family members were not affected.

Blood tests including HIV-ELISA were unremarkable with the exception of TPPA (1:160). Standard bacterial cultures (McConkey-sheep blood agar, 37°C) from skin swabs revealed coagulase-negative *Staphylococcus aureus*. Cultures under microaerophilic and dark conditions on brain–heart infusion agar (pH 7.1, 37°C) were negative for *Propionibacterium* species. *Treponema pallidum* DNA was not found after PCR in PMH lesion.



**Figure 1** (A) Disseminated progressive macular hypomelanosis in a 29-year-old female patient. (B) No follicular fluorescence under Wood's light (UVA 320–400 nm), right flank part.



## Take-home messages


- ▶ Progressive macular hypomelanosis (PMH) is a rare aetiologically unknown pigmentation anomaly characterised by small, immature melanosomes containing low-density melanin.
- ▶ The diagnosis of PMH is based on the ultrastructural examination of melanosomes.

A staining showed normal melanocyte morphology but reduced numbers in the basal layer (figure 2C). Electron microscopy revealed smaller and aggregated melanosomes in the affected areas compared with unaffected skin (figure 3).

Phototherapy was declined by the patient. However, encouraged by a report from the literature,<sup>4</sup> we tried 2.5% benzoyl peroxide cream treatment twice daily for a month despite the lack of evidence of *Propionibacterium*. We did not observe any effect after 6 months' follow-up.

No consensus has been reached so far regarding the aetiology of PMH. Based on the observation of follicular red fluorescence under Wood's light in 50 from 291 PMH patients, and isolates of *Propionibacterium* from lesional, but not from healthy skin in six patients, a bacterial aetiology for PMH was proposed.<sup>5</sup> This provided the rationale for a randomised, within-patient, left–right comparison trial between topical antimicrobial treatment (5% benzoyl peroxide gel and 1% clindamycin lotion, bcUVA) and anti-inflammatory treatment (0.05% fluticasone cream, fUVA), both combined with UVA three times/week for 14 weeks.<sup>4</sup> Both treatment arms achieved temporary repigmentation or hyperpigmentation. At the 12-week examination, lesional (re)pigmentation was found to approximate the pigmentation of normal skin in both arms with a difference of 0.9 colorimetric units. A complete repigmentation was observed only in 62% (28/45) bcUVA- treated arms compared to 22% (10/45) after fUVA at the 12-week follow-up. The remaining sites showed either no or incomplete repigmentation.<sup>4</sup>


The study leaves many questions unanswered: To what extent does the topical treatment contribute to the effect of UVA? Other studies employing only phototherapy have demonstrated beneficial effects of UVB<sup>6</sup> or sun light.<sup>7</sup> Could the lower degree of pigmentation achieved in the fUVA arm have been brought about by corticosteroid? If the cause of PMH was an infection, why would anti-inflammatory treatment be effective as well? Why was the treatment effect transient? To evaluate the efficacy of antimicrobial therapy, treatment versus placebo, vehicle plus UVA would have been preferable.



**Figure 2** Histological stains and immunohistochemistry of healthy (left) and lesional (right) skin from the back: a marked reduction of pigment in the basal layer of the epidermis in lesional skin (right) on (A) H&E and (B) Fontana–Masson staining; (C) a reduction in the number of melanocytes in lesional skin (right) in Melan A staining.

A marked reduction of pigment in the basal layer of the epidermis and a sparse lymphohistiocytic infiltrate could be seen in lesional skin on H&E (figure 2A) and Fontana–

Masson staining (figure 2B). Bacteria and fungi were absent in both hair follicles and inter-follicular epidermis on H&E or periodic acid Schiff-stained sections. Melan



**Figure 3** Electron microscopy of healthy (left) and lesional (right) skin parts of the back; immature melanosomes look smaller and aggregated in the lesional skin (×20 000).

Why do acne patients, whose skin is densely colonised by propionibacteria, never exhibit signs of hypopigmentation or PMH? One recent study identified *Propionibacterium* species other than *Propionibacterium acnes* from the skin of 8 out of 14 PMH patients, where the remaining 6 patients were found to harbour *P acnes* exclusively on their skin.<sup>8</sup> This definitely put the existence of any causative or PMH-specific species in doubt.

As reported earlier in this article,<sup>3</sup> we did not find any signs of *Propionibacterium* colonisation of lesional skin by Wood's light examination, microbiological analysis or pathology. The diagnosis of PMH was confirmed by histology and electron microscopy. Other differential diagnosis of hypopigmentation (syphilis, pityriasis versicolor, pityriasis alba, leprosy, incontinentia pigmenti, mycosis fungoides or arsenic hypomelanosis) could be excluded by clinical signs, history, laboratory and histopathology.

The follicular fluorescence under Wood's light is obviously an indicator of *Propionibacterium* colonisation, but the prevalence of these bacteria has to be evaluated epidemiologically in PMH patients and healthy controls. Our observations as well as those of others<sup>3</sup> show

that PMH occurs in the absence of *Propionibacterium*. We therefore rather favour the hypothesis of a genetic background of PMH as proposed by Guillet *et al*<sup>2</sup> with an impaired melanosomal maturation process giving rise to smaller melanosomes, containing low-density melanin.

**Alexander Vasilevic Kuznetsov,<sup>1,2</sup>  
Michael Joseph Flaig,<sup>1</sup> Thomas Ruzicka,<sup>1</sup>  
Thomas Herzinger<sup>1</sup>**

<sup>1</sup>Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich, Germany; <sup>2</sup>Cancer Research UK Cambridge Research Institute, University of Cambridge, Cambridge, UK

**Correspondence to** Dr Alexander V Kuznetsov, Cancer Research UK Cambridge Research Institute, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK; alexander.kuznetsov@med.uni-muenchen.de

AVK and MJF contributed equally to this work.

**Competing interests** None.

**Patient consent** Obtained.

**Provenance and peer review** Not commissioned; externally peer reviewed.

Published Online First 13 April 2011

*J Clin Pathol* 2011;**64**:734–736.  
doi:10.1136/jcp.2010.084780

## REFERENCES

1. **Guillet G**, Gauthier Y, Helenon R. *Hypomelanose Maculaire Progressive Du Tronc (Hypopigmentation Primitive Acquisée Des Antilles)*. Paris: Soc Fr Dermatol, 1985.
2. **Guillet G**, Helenon R, Gauthier Y, *et al*. Progressive macular hypomelanosis of the trunk: primary acquired hypomelanosis. *J Cutan Pathol* 1988;**15**:286–9.
3. **Neynaber S**, Kirschner C, Kamann S, *et al*. Progressive macular hypomelanosis: a rarely diagnosed hypopigmentation in Caucasians. *Dermatol Res Pract* 2009;607682. Epub 2009 Jun 1.
4. **Relyveld GN**, Kingswijk MM, Reitsma JB, *et al*. Benzoyl peroxide/ clindamycin/ UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. *J Am Acad Dermatol* 2006;**55**:836–43.
5. **Westerhof W**, Relyveld GN, Kingswijk MM, *et al*. *Propionibacterium acnes* and the pathogenesis of progressive macular hypomelanosis. *Arch Dermatol* 2004;**140**:210–14.
6. **Kwah YC**, Chong WS, Thiam-Seng Theng C, *et al*. Treatment of progressive macular hypomelanosis with narrow-band ultraviolet B phototherapy. *Photodermatol Photoimmunol Photomed* 2010;**26**:153–5.
7. **Perman J**, Sheth P, Lucky AW. Progressive macular hypomelanosis in a 16-year old. *Pediatr Dermatol* 2008;**1**:63–5.
8. **Relyveld GN**, Westerhof W, Woudenberg J, *et al*. Progressive macular hypomelanosis is associated with a putative *Propionibacterium* species. *J Invest Dermatol* 2010;**130**:1182–4.



## Progressive macular hypomelanosis Guillet-Hélénon: structural and immunohistochemical findings

Alexander Vasilevic Kuznetsov, Michael Joseph Flaig, Thomas Ruzicka  
and Thomas Herzinger

*J Clin Pathol* 2011 64: 734-736 originally published online April 13, 2011  
doi: 10.1136/jcp.2010.084780

---

Updated information and services can be found at:  
<http://jcp.bmj.com/content/64/8/734>

---

*These include:*

### References

This article cites 6 articles, 0 of which you can access for free at:  
<http://jcp.bmj.com/content/64/8/734#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the  
box at the top right corner of the online article.

---

### Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>